Discovery of novel biomarkers for Epstein Barr Virus (EBV) infection related cancers – PTLD and cross-pathogen (Old ID 26525)

Principal Investigator

There is a large body of evidence indicating that Epstein-Barr virus (EBV) actively contributes to the pathogenesis of multiple tumours. We hypothesize that the antibody response to EBV is altered in infection-related cancers. We are comprehensively assessing the antibody response to EBV in individuals with and without cancer (cases and controls) using our proprietary EBV proteome array, to identify an antibody signature which predicts cancer risk. The ultimate goal is an immunodiagnostic test to identify individuals in the general population who are at high risk of developing infection-related cancers. Extending previous studies, we will probe defined samples from PTLD and other EBV-infection related cancer studies provided by colleagues at Moffitt Cancer Center and Baylor College of Medicine to define IgA and IgG antibody repertoires

08 Apr 2019 - 31 Mar 2020

N/A